RecruitingNCT06181994
Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)
Outcomes of Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma; Middle Meningeal Artery Embolization for Chronic Subdural Hematoma (MESH)
Sponsor
Montefiore Medical Center
Enrollment
5,000 participants
Start Date
Dec 5, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This multi-center retrospective cohort study aims to investigate the real-world outcomes of chronic subdural hematoma treated with MMAE, including clinical effectiveness, recurrence rates, and safety profile.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Consecutive adult patients (18 yrs. of age or older)
- Endovascular embolization of middle meningeal artery using any embolization material:
- PVA particles; Onyx, nBCA glue; dimethyl sulfoxide, microcoils, PVA with microcoils
Exclusion Criteria1
- Endovascular embolization of middle meningeal artery using any other embolization material
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(19)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06181994
Related Trials
Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study
NCT0634779631 locations
Implementation of an Enhanced Recovery Pathway for Burr-hole Drainage in Patients With a Chronic Subdural Hematoma
NCT074214531 location
Neuroendoscopy-assisted Drainage Versus Burr Hole Drainage for Chronic Subdural Hematoma
NCT0714442324 locations
Efficacy of a Minimally Invasive Therapy Adjuvant to the Standards of Care by Cyanoacrylate Embolization
NCT0537468111 locations
Microfabricated Microcatheter Advantages in Middle Meningeal Artery Embolization: an Early Experience at a Single Center
NCT073245511 location